---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-22-027801"
form_type: "8-K"
ticker: "NAGE"
cik: "0001386570"
company_name: "Niagen Bioscience, Inc."
filed_at: "2022-11-02T23:59:59+00:00"
generated_at: "2026-06-22T13:00:55.174094+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# ChromaDex Q3 net sales $17.1M, net loss narrows to $1.0M; approaches cash flow breakeven

## Summary
- Net loss of $1.0M ($0.01 loss per share) vs $8.8M loss in Q3 2021; Adjusted EBITDA loss narrowed to $1.2M.
- Gross margin 59.8% (down from 61.1% YoY); operating expenses cut $6.1M to $13.3M, driven by lower legal and marketing costs.
- Signed long-term supply agreement with Nestlé Health Science with ~$2.0M initial purchase commitment; raised $7.7M from Nestlé and strategic investors.
- JV signed to pursue Blue Hat approval for Tru Niagen in Mainland China; clinical study in JACC found Niagen safe in heart failure patients.
- Tru Niagen e-commerce sales steady but B2B sales declined due to COVID-19 headwinds and macro factors.

## SEC filing metadata
- accession: 0001628280-22-027801
- form_type: 8-K
- ticker: NAGE
- cik: 0001386570
- company_name: Niagen Bioscience, Inc.
- filed_at: 2022-11-02T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1386570/000162828022027801/0001628280-22-027801-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1386570/000162828022027801/cdxc-20221102.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-22-027801
- JSON: https://secwatch.observer/filing/0001628280-22-027801.json
- Plain text: https://secwatch.observer/filing/0001628280-22-027801.txt

## Key facts
- Earnings Releases
  Niagen Bioscience, Inc. reported the quarter ended September 30, 2022 results: revenue $17.1 million, net income $1.0 million or $(0.01) per share, EPS $(0.01) per share.
  - Period: the quarter ended September 30, 2022
  - Revenue: $17.1 million
  - Net income: $1.0 million or $(0.01) per share
  - EPS: $(0.01) per share
  - Result: reported results
  source text: ChromaDex Corporation Reports Third Quarter 2022 Financial Results Total net sales of $17.1 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1386570/000162828022027801/0001628280-22-027801-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.